Fatigue (Central Nervous System) - Drugs in Development, 2021

March 2021 | 37 pages | ID: F873503AE812EN
Global Markets Direct

Abstracts

Fatigue (Central Nervous System) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fatigue - Drugs in Development, 2021, provides an overview of the Fatigue (Central Nervous System) pipeline landscape.

Fatigue also referred to as tiredness, exhaustion, lethargy, listlessness, and describes a physical and/or mental state of being tired and weak. Signs and symptoms include aching or sore muscles, painful lymph nodes, chronic (long-term) tiredness, dizziness, headache, irritability and loss of appetite.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fatigue - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Fatigue (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fatigue (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Unknown stages are 2, 3 and 2 respectively.

Fatigue (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Fatigue (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Fatigue (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Fatigue (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Fatigue (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Fatigue (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Fatigue (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Fatigue (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Fatigue - Overview
Fatigue - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Fatigue - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fatigue - Companies Involved in Therapeutics Development
Aoxing Pharmaceutical Company Inc
Contero Therapeutics
Helsinn Group
K-Pax Pharmaceuticals Inc
Primetime Life Sciences LLC
Resolys Bio Inc
Sunny Pharmtech Inc
Fatigue - Drug Profiles
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Chronic Pain and Fatigue - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
caffeine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPAX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLS-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fatigue - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Fatigue, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Fatigue - Pipeline by Aoxing Pharmaceutical Company Inc, 2021
Fatigue - Pipeline by Contero Therapeutics, 2021
Fatigue - Pipeline by Helsinn Group, 2021
Fatigue - Pipeline by K-Pax Pharmaceuticals Inc, 2021
Fatigue - Pipeline by Primetime Life Sciences LLC, 2021
Fatigue - Pipeline by Resolys Bio Inc, 2021
Fatigue - Pipeline by Sunny Pharmtech Inc, 2021
Fatigue - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Fatigue, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021